Zentalis posted a Q2 net loss of $42.29 million, or $0.59 a share, widening from a $26.87 million loss a year earlier.
Operating loss widened to $44.39 million, while research and development expense rose 27.53% to $35.16 million on a $7 million Phase 3 ASPENOVA milestone.
Cash position, FDA update and trial timeline
Cash, cash equivalents and marketable securities fell to $174.61 million at June 30 from $245.89 million at Dec. 31; runway is projected into late 2027.
The FDA raised no objection to continued study of azenosertib at 400 mg QD 5:2; the accelerated approval strategy for Cyclin E1-positive PROC remains intact.
DENALI Parts 2a and 2b completed enrollment, Part 2c is enrolling, and integrated Part 2 topline data are expected in 1H 2027.
ZNTL•
